At the World Federation of Hemophilia World Congress, Spark Therapeutics and Pfizer Diagnostics announced factor IX gene transfer vector SPK-9001 success rates in 15 hemophilia B participants. Click or tap here for their press release.
Posts - Bleeding Disorders
Jun 7, 2018 1:04pm
Precision BioLogic Inc. presented MNBA data at the World Federation of Hemophilia (WFH) 2018 World Congress in Glasgow, Scotland, May 20–24. Recognizing the need to improve factor VIII (FVIII ) inhibitor testing for people with hemophilia A, the company studied the agreement between a chromogenic modified Nijmegen-Bethesda assay (MNBA) and a qualitative ELISA test in the detection of FVIII inhibitors in plasma samples.
May 11, 2018 3:27am
From Heather DeVries, Indiana University Health: Greetings George! One of the facilities in our system is questioning our critical fibrinogen level. Anything <70 mg/dL